The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
Open accessAbstract
Although antiestrogen therapies targeting estrogen receptor (ER) α signaling prevent disease recurrence in the majority of patients with hormone-dependent breast cancer, a significant fraction of patients exhibit de novo or acquired resistance. Currently, the only accepted mechanism linked with endocrine resistance is amplification or overexpression of the ERBB2 (human epidermal growth factor receptor 2 [HER2]) proto-oncogene. Experimental and clinical evidence suggests that hyperactivation of the phosphatidylinositol 3-kinase (PI3K) pathway, the most frequently mutated pathway in breast cancer, promotes antiestrogen resistance. PI3K is a major signaling hub downstream of HER2 and other receptor tyrosine kinases. PI3K activates several molecules involved in cell-cycle progression and survival, and in ER-positive breast cancer cells, it promotes estrogen-dependent and -independent ER transcriptional activity. Preclinical tumor models of antiestrogen-resistant breast cancer often remain sensitive to estrogens and PI3K inhibition, suggesting that simultaneous targeting of the PI3K and ER pathways may be most effective. Herein, we review alterations in the PI3K pathway associated with resistance to endocrine therapy, the state of clinical development of PI3K inhibitors, and strategies for the clinical investigation of such drugs in hormone receptor–positive breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
She, Q.-B., Chandarlapaty, S., Ye, Q., Lobo, J., Haskell, K. M., Leander, K. R., DeFeo-Jones, D., Huber, H. E., & Rosen, N. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003065 · Cited by 301
RetractedSørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Dérijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., & Davis, R. J. (1994) · Cell · doi:10.1016/0092-8674(94)90380-8 · Cited by 3,188
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Franke, T. F., Yang, S.-I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R., & Tsichlis, P. N. (1995) · Cell · doi:10.1016/0092-8674(95)90534-0 · Cited by 2,006
Hibi, M., Lin, A., Smeal, T., Minden, A., & Karin, M. (1993) · Genes & Development · doi:10.1101/gad.7.11.2135 · Cited by 1,886
Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70257-6 · Cited by 1,674
Minden, A., Lin, A., Claret, F.-X., Abo, A., & Karin, M. (1995) · Cell · doi:10.1016/s0092-8674(05)80019-4 · Cited by 1,478
Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase
Simoncini, T., Hafezi-Moghadam, A., Brazil, D. P., Ley, K., Chin, W. W., & Liao, J. K. (2000) · Nature · doi:10.1038/35035131 · Cited by 1,436
The small GTP-binding proteins Rac1 and Cdc42regulate the activity of the JNK/SAPK signaling pathway
Coso, O. A., Chiariello, M., Yu, J.-C., Teramoto, H., Crespo, P., Xu, N., Miki, T., & Silvio Gutkind, J. (1995) · Cell · doi:10.1016/s0092-8674(05)80018-2 · Cited by 1,397
Filardo, E. J. (2000) · Molecular Endocrinology · doi:10.1210/me.14.10.1649 · Cited by 1,383
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,292
Shou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., & Schiff, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,153
Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134
An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054
Johnston, S., Pippen, J., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., Gomez, H. L., Romieu, G., Manikhas, A., Kennedy, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3734 · Cited by 1,025
Whitman, M., Downes, C. P., Keeler, M., Keller, T., & Cantley, L. (1988) · Nature · doi:10.1038/332644a0 · Cited by 1,016
Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α
Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali, S., & Nakshatri, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010840200 · Cited by 968
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967
Phosphoinositide 3-kinases: A conserved family of signal transducers
Vanhaesebroeck, B., Leevers, S. J., Panayotou, G., & Waterfield, M. D. (1997) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(97)01061-x · Cited by 954
(2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70385-6 · Cited by 919
Mutation of the PIK3CA Gene in Ovarian and Breast Cancer
Campbell, I. G., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 916
Gingras, A.-C., Kennedy, S. G., O'Leary, M. A., Sonenberg, N., & Hay, N. (1998) · Genes & Development · doi:10.1101/gad.12.4.502 · Cited by 886
Kaufman, B., Mackey, J. R., Clemens, M. R., Bapsy, P. P., Vaid, A., Wardley, A., Tjulandin, S., Jahn, M., Lehle, M., Feyereislova, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6847 · Cited by 843
Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., & Osborne, C. K. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01961241 · Cited by 750
Folkes, A. J., Ahmadi, K., Alderton, W. K., Alix, S., Baker, S. J., Box, G., Chuckowree, I. S., Clarke, P. A., Depledge, P., Eccles, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800295d · Cited by 741
FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Turner, N., Pearson, A., Sharpe, R., Lambros, M., Geyer, F., Lopez-Garcia, M. A., Natrajan, R., Marchio, C., Iorns, E., Mackay, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3746 · Cited by 732
Bachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.-M., Freyer, G., Abadie-Lacourtoisie, S., Eymard, J.-C., Debled, M., Spaëth, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.0708 · Cited by 703
Bendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., De Buck, S. S., Ru, Q. C., Peters, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 684
Dowsett, M., Smith, I. E., Ebbs, S. R., Dixon, J. M., Skene, A., A'Hern, R., Salter, J., Detre, S., Hills, M., & Walsh, G. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djk020 · Cited by 665
Ellis, M. J., Tao, Y., Luo, J., A'Hern, R., Evans, D. B., Bhatnagar, A. S., Chaudri Ross, H. A., von Kameke, A., Miller, W. R., Smith, I., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn309 · Cited by 653
Baselga, J., Gelmon, K. A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V. A., Ross, G. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2024 · Cited by 643
Baselga, J., Semiglazov, V., van Dam, P., Manikhas, A., Bellet, M., Mayordomo, J., Campone, M., Kubista, E., Greil, R., Bianchi, G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8391 · Cited by 636
Fos-Associated Protein p39 Is the Product of the jun Proto-Oncogene
Rauscher, F. J., Cohen, D. R., Curran, T., Bos, T. J., Vogt, P. K., Bohmann, D., Tjian, R., & Franza, B. R. (1988) · Science · doi:10.1126/science.3130660 · Cited by 629
Pietras, R. J., Arboleda, J., Dm, R., Wongvipat, N., Pegram, M. D., Ramos, L., Cm, G., Mg, P., Sliwkowski, M. X., & Dj, S. (1995) · PubMed · Cited by 603
Miller, T. W., Hennessy, B. T., González-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., García-Echeverría, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 551
Self-citationArpino, G., Wiechmann, L., Osborne, C. K., & Schiff, R. (2008) · Endocrine Reviews · doi:10.1210/er.2006-0045 · Cited by 549
Yap, T. A., Yan, L., Patnaik, A., Fearen, I., Olmos, D., Papadopoulos, K., Baird, R. D., Delgado, L., Taylor, A., Lupinacci, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5263 · Cited by 539
Nature of Functional Estrogen Receptors at the Plasma Membrane
Pedram, A., Razandi, M., & Levin, E. R. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0525 · Cited by 522
Saal, L. H., Johansson, P., Holm, K., Gruvberger-Saal, S. K., She, Q.-B., Maurer, M., Koujak, S., Ferrando, A. A., Malmström, P., Memeo, L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702507104 · Cited by 520
Breast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells
Isakoff, S. J., Engelman, J. A., Irie, H. Y., Luo, J., Brachmann, S. M., Pearline, R. V., Cantley, L. C., & Brugge, J. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2612 · Cited by 509
Gutierrez, M. C., Detre, S., Johnston, S., Mohsin, S. K., Shou, J., Allred, D. C., Schiff, R., Osborne, C. K., & Dowsett, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.172 · Cited by 489
Massarweh, S., Osborne, C. K., Creighton, C. J., Qin, L., Tsimelzon, A., Huang, S., Weiss, H., Rimawi, M., & Schiff, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2707 · Cited by 488
Drug discovery approaches targeting the PI3K/Akt pathway in cancer
Garcia-Echeverria, C., & Sellers, W. R. (2008) · Oncogene · doi:10.1038/onc.2008.246 · Cited by 473
Garrett, J. T., Olivares, M. G., Rinehart, C., Granja-Ingram, N. D., Sánchez, V., Chakrabarty, A., Dave, B., Cook, R. S., Pao, W., McKinely, E., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016140108 · Cited by 467
Self-citationLi, L., Haynes, M. P., & Bender, J. R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0831079100 · Cited by 465
Gewinner, C., Wang, Z. C., Richardson, A., Teruya-Feldstein, J., Etemadmoghadam, D., Bowtell, D., Barretina, J., Lin, W. M., Rameh, L., Salmena, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.006 · Cited by 461
Zhao, L., & Vogt, P. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712169105 · Cited by 437
(1988) · PubMed · Cited by 416
Song, R. X.-D., McPherson, R. A., Adam, L., Bao, Y., Shupnik, M., Kumar, R., & Santen, R. J. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.1.0748 · Cited by 407
Law, J. H., Habibi, G., Hu, K., Masoudi, H., Wang, M. Y. C., Stratford, A. L., Park, E., Gee, J. M. W., Finlay, P., Jones, H. E., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2755 · Cited by 401
Wang, Z., Zhang, X., Shen, P., Loggie, B. W., Chang, Y., & Deuel, T. F. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603339103 · Cited by 380
Xia, W., Bacus, S., Hegde, P., Husain, I., Strum, J., Liu, L., Paulazzo, G., Lyass, L., Trusk, P., Hill, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602468103 · Cited by 374
Anderson, K. E., Coadwell, J., Stephens, L. R., & Hawkins, P. T. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70274-x · Cited by 360
Loi, S., Haibe-Kains, B., Majjaj, S., Lallemand, F., Durbecq, V., Larsimont, D., Gonzalez-Angulo, A. M., Pusztai, L., Symmans, W. F., Bardelli, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907011107 · Cited by 356
Chakrabarty, A., Sánchez, V., Kuba, M. G., Rinehart, C., & Arteaga, C. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018001108 · Cited by 347
Self-citationPrognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer
Al-Kuraya, K., Schraml, P., Torhorst, J., Tapia, C., Zaharieva, B., Novotny, H., Spichtin, H., Maurer, R., Mirlacher, M., Köchli, O., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1945 · Cited by 347
Di Nicolantonio, F., Arena, S., Tabernero, J., Grosso, S., Molinari, F., Macarulla, T., Russo, M., Cancelliere, C., Zecchin, D., Mazzucchelli, L., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci37539 · Cited by 343
De Laurentiis, M., Arpino, G., Massarelli, E., Ruggiero, A., Carlomagno, C., Ciardiello, F., Tortora, G., D'Agostino, D., Caputo, F., Cancello, G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2569 · Cited by 340
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
Janku, F., Tsimberidou, A. M., Garrido-Laguna, I., Wang, X., Luthra, R., Hong, D. S., Naing, A., Falchook, G. S., Moroney, J. W., Piha-Paul, S. A., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0994 · Cited by 331
Robertson, J. F. R., Llombart-Cussac, A., Rolski, J., Feltl, D., Dewar, J., Macpherson, E., Lindemann, J., & Ellis, M. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1136 · Cited by 310
Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
Rhodes, N., Heerding, D. A., Duckett, D. R., Eberwein, D. J., Knick, V. B., Lansing, T. J., McConnell, R. T., Gilmer, T. M., Zhang, S.-Y., Robell, K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5783 · Cited by 295
Pérez-Tenorio, G., Alkhori, L., Olsson, B., Waltersson, M. A., Nordenskjöld, B., Rutqvist, L. E., Skoog, L., & Stål, O. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1609 · Cited by 292
Somatic Mutations in p85α Promote Tumorigenesis through Class IA PI3K Activation
Jaiswal, B. S., Janakiraman, V., Kljavin, N. M., Chaudhuri, S., Stern, H. M., Wang, W., Kan, Z., Dbouk, H. A., Peters, B. A., Waring, P., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.016 · Cited by 289
Fedele, C. G., Ooms, L. M., Ho, M., Vieusseux, J., O'Toole, S. A., Millar, E. K., Lopez-Knowles, E., Sriratana, A., Gurung, R., Baglietto, L., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015245107 · Cited by 283
Garlich, J. R., De, P., Dey, N., Su, J. D., Peng, X., Miller, A., Murali, R., Lu, Y., Mills, G. B., Kundra, V., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-0669 · Cited by 279
Creighton, C. J., Fu, X., Hennessy, B. T., Casa, A. J., Zhang, Y., Gonzalez-Angulo, A. M., Lluch, A., Gray, J. W., Brown, P. H., Hilsenbeck, S. G., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2594 · Cited by 258
Arpino, G., Green, S. J., Allred, D. C., Lew, D., Martino, S., Osborne, C. K., & Elledge, R. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0110 · Cited by 255
Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer
Monni, O., Bärlund, M., Mousses, S., Kononen, J., Sauter, G., Heiskanen, M., Paavola, P., Avela, K., Chen, Y., Bittner, M. L., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091582298 · Cited by 252
Fan, M., Yan, P. S., Hartman-Frey, C., Chen, L., Paik, H., Oyer, S. L., Salisbury, J. D., Cheng, A. S. L., Li, L., Abbosh, P. H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1666 · Cited by 248
S6 Kinase 1 Regulates Estrogen Receptor α in Control of Breast Cancer Cell Proliferation
Yamnik, R. L., Digilova, A., Davis, D. C., Brodt, Z. N., Murphy, C. J., & Holz, M. K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807532200 · Cited by 246
PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Stemke-Hale, K., Sahin, A., Liu, S., Barrera, J. A., Burgues, O., Lluch, A. M., Chen, H., Hortobagyi, G. N., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1089 · Cited by 219
Crowder, R. J., Phommaly, C., Tao, Y., Hoog, J., Luo, J., Perou, C. M., Parker, J. S., Miller, M. A., Huntsman, D. G., Lin, L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4450 · Cited by 218
Smith, I. E., Walsh, G., Skene, A., Llombart, A., Mayordomo, J. I., Detre, S., Salter, J., Clark, E., Magill, P., & Dowsett, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6578 · Cited by 201
Dupont Jensen, J., Laenkholm, A.-V., Knoop, A., Ewertz, M., Bandaru, R., Liu, W., Hackl, W., Barrett, J. C., & Gardner, H. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1133 · Cited by 200
Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver
Amin, D. N., Sergina, N., Ahuja, D., McMahon, M., Blair, J. A., Wang, D., Hann, B., Koch, K. M., Shokat, K. M., & Moasser, M. M. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000389 · Cited by 175
Ellis, M. J., Tao, Y., Young, O., White, S., Proia, A. D., Murray, J., Renshaw, L., Faratian, D., Thomas, J., Dowsett, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3034 · Cited by 173
Robertson, J. F. R., Lindemann, J. P. O., Llombart-Cussac, A., Rolski, J., Feltl, D., Dewar, J., Emerson, L., Dean, A., & Ellis, M. J. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2192-4 · Cited by 172
Miller, T. W., Pérez-Torres, M., Narasanna, A., Guix, M., Stål, O., Pérez-Tenorio, G., Gonzalez-Angulo, A. M., Hennessy, B. T., Mills, G. B., Kennedy, J. P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0042 · Cited by 168
Self-citationFrogne, T., Benjaminsen, R. V., Sonne‐Hansen, K., Sørensen, B. S., Nexø, E., Lænkholm, A., Rasmussen, L. M., Riese, D. J., de Crémoux, P., Stenvang, J., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0011-8 · Cited by 157
Rochlitz, C. F., Scott, G. K., Dodson, J. M., Liu, E., Dollbaum, C. M., Smith, H. S., & Benz, C. C. (1989) · PubMed · Cited by 157
Cristofanilli, M., Valero, V., Mangalik, A., Royce, M., Rabinowitz, I., Arena, F. P., Kroener, J. F., Curcio, E., Watkins, C. L., Bacus, S. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2282 · Cited by 156
Maurer, M. S., Su, T., Saal, L. H., Koujak, S., Hopkins, B. D., Barkley, C. R., Wu, J., Nandula, S. V., Dutta, B., Xie, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0820 · Cited by 143
Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen
Shoman, N. M., Klassen, S., McFadden, A., Bickis, M., Torlakovic, E., & Chibbar, R. (2004) · Modern Pathology · doi:10.1038/modpathol.3800296 · Cited by 142
Ellis, M. J., Li, L., Crowder, R. J., Yu, T., Hoog, J., Snider, J., Davies, S. R., DeSchryver, K., Evans, D. B., Steinseifer, J., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0575-y · Cited by 140
Miller, T. W., Forbes, J. T., Shah, C., Wyatt, S. K., Manning, H. C., Olivares, M. G., Sanchez, V. M., Dugger, T. C., Granja, N. D. M., Narasanna, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1665 · Cited by 139
Self-citationmTOR inhibitors in the treatment of cancer
Fasolo, A., & Sessa, C. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.11.1717 · Cited by 138
Logan, S. K., Falasca, M., Hu, P. J., & Schlessinger, J. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.10.5784 · Cited by 135
PIK3CA Mutations in In situ and Invasive Breast Carcinomas
Miron, A., Varadi, M., Carrasco, D. R., Li, H., Luongo, L., Kim, H. J., Park, S. Y., Cho, E. Y., Lewis, G., Kehoe, S. M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-08-2660 · Cited by 135
Petz, L. N., Ziegler, Y., Loven, M. A., & Nardulli, A. M. (2002) · Endocrinology · doi:10.1210/en.2002-220369 · Cited by 133
Ellis, P., Smith, I. E., DETRE, S. I., Burton, S., Salter, J., A’Hern, R., Walsh, G., Johnston, S. R. D., & Dowsett, M. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1005933815809 · Cited by 126
Luminal Expression of PIK3CA Mutant H1047R in the Mammary Gland Induces Heterogeneous Tumors
Meyer, D. S., Brinkhaus, H., Müller, U., Müller, M., Cardiff, R. D., & Bentires‐Alj, M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3827 · Cited by 125
Unraveling the Mechanisms of Endocrine Resistance in Breast Cancer: New Therapeutic Opportunities
Massarweh, S. A., & Schiff, R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2540 · Cited by 125
Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen
Lipton, A., Ali, S. M., Leitzel, K., Demers, L., Harvey, H. A., Chaudri‐Ross, H. A., Brady, C., Wyld, P. J., & Carney, W. P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.098 · Cited by 124
Sabnis, G. J., Schayowitz, A., Goloubeva, O. G., Macedo, L. F., & Brodie, A. M. H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-0857 · Cited by 123
Should individual PI3 kinase isoforms be targeted in cancer?
Jia, S., Roberts, T. M., & Zhao, J. J. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.007 · Cited by 120
Burris, H. A., Rodon, J. A., Sharma, S., Herbst, R. S., Tabernero, J. M., Infante, J. R., Silva, A. M. E., Demanse, D., Hackl, W., & Baselga, J. M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3005 · Cited by 109
A Structural Comparison of Inhibitor Binding to PKB, PKA and PKA-PKB Chimera
Davies, T. G., Verdonk, M. L., Graham, B. L., Saalau-Bethell, S. M., Hamlett, C. C. F., McHardy, T., Collins, I., Garrett, M. D., Workman, P., Woodhead, S. J., et al. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.01.004 · Cited by 91
Role of receptor complexes in the extranuclear actions of estrogen receptor α in breast cancer
Song, R. X.-D., Fan, P., Yue, W., Chen, Y., & Santen, R. J. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01322 · Cited by 78
Edelman, G. M., Bedell, C., Shapiro, G. I., Pandya, S. S., Kwak, E. L., Scheffold, C., Nguyen, L. T., Laird, A., Baselga, J. M., & Rodon, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3004 · Cited by 77
Assersohn, L., Salter, J., Powles, T. J., A’Hern, R., Makris, A., Gregory, R. K., Chang, J. C., & Dowsett, M. (2003) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000003968.45511.3f · Cited by 69
Linking somatic genetic alterations in cancer to therapeutics
Stuart, D. D., & Sellers, W. R. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.02.001 · Cited by 68
Johnston, S. R. D., Семиглазов, В. Ф., Manikhas, G. M., Spaëth, D., Romieu, G., Dodwell, D. J., Wardley, A. M., Neven, P., Bessems, A., Park, Y. C., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9726-1 · Cited by 66
Maira, S.-M., Voliva, C. F., & García-Echeverría, C. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.2.223 · Cited by 64
The Role of Amphiregulin in Exemestane-Resistant Breast Cancer Cells: Evidence of an Autocrine Loop
Wang, X., Masri, S., Phung, S., & Chen, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5544 · Cited by 64
Toral‐Barza, L., Zhang, W., Huang, X., McDonald, L. A., Salaski, E. J., Barbieri, L. R., Ding, W., Krishnamurthy, G., Hu, Y. B., Lucas, J., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0211 · Cited by 63
Bachelot, T., Bourgier, C., Cropet, C., Guastalla, J. P., Ferrero, J.-M., Falandry, C., Soulié, P., Eymard, J.-C., Debled, M., Spaëth, D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.sabcs10-s1-6 · Cited by 59
Sabnis, G. J., Goloubeva, O. G., Jelovac, D., Schayowitz, A., & Brodie, A. M. H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2466 · Cited by 59
Generali, D., Fox, S. B., Brizzi, M. P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1046 · Cited by 55
Baselga, J. M., Jonge, M. J. D., Rodon, J. A., Burris, H. A., Birle, D. C., Buck, S. S. D., Demanse, D., Ru, Q. C., Goldbrunner, M., & Bendell, J. C. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3003 · Cited by 53
Furman, R. R., Byrd, J. C., Flinn, I. W., Coutre, S. E., Benson, D. M., Brown, J. R., Kahl, B. S., Wagner‐Johnston, N. D., Giese, N. A., & Yu, A. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3032 · Cited by 43
Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth
DeNardo, D. G., Cuba, V. L., Kim, H.-T., Wu, K., Lee, A. V., & Brown, P. H. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.07.006 · Cited by 34
Voliva, C. F., Pecchi, S., Burger, M. T., Nagel, T., Schnell, C., Fritsch, C. M., Brachmann, S. M., Menezes, D. L. D., Knapp, M. S., Shoemaker, K. R., et al. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-4498 · Cited by 32
Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells
Yue, W., Wang, J., Li, Y., Fan, P., & Santen, R. J. (2005) · International Journal of Cancer · doi:10.1002/ijc.21222 · Cited by 31
Robertson, J. F. R., Lindemann, J. P. O., Llombart‐Cussac, A., Rolski, J., Feltl, D., Dewar, J., Emerson, L., Dean, A., & Ellis, M. (2010) · Cancer Research · doi:10.1158/0008-5472.sabcs10-s1-3 · Cited by 30
Robertson, J. F. R., Dixon, J. M., Sibbering, D. M., Jahan, A., Ellis, I. O., Channon, E., Nicholson, R. I., & Gee, J. M. W. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-24 · Cited by 16
Cited by
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Targeting the PI3K pathway in cancer: are we making headway?
Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
Alzahrani, A. S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.009 · Cited by 1,054
The PI3K/AKT Pathway as a Target for Cancer Treatment
Mayer, I. A., & Arteaga, C. L. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-062913-051343 · Cited by 822
Self-citationNon-genetic mechanisms of therapeutic resistance in cancer
Marine, J.-C., Dawson, S.-J., & Dawson, M. A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-00302-4 · Cited by 635
Metadata
- Authors
- Miller, T. W., Balko, J. M., & Arteaga, C. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-11-20
- Volume
- 29
- Issue
- 33
- Pages
- 4452-4461
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2014001512
- Cited by
- 413
- References
- 125
- FWCI
- 13.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.